Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
REKR$0.27+0.04(+16.80%)NASDAQ Grants Rekor Systems Six-Month Extension to Regain Compliance with Minimum Bid Price Requirement[10:05:48 AM ET]HAS$117.35-0.61(-0.52%)Hasbro Names Dan Ayoub President of Wizards of the Coast & Hasbro Digital Games[10:01:00 AM ET]HAS$117.35-0.61(-0.52%)Hasbro Announces New Original YouTube Series, Play-Doh with Margo[10:00:00 AM ET]UNF$242.00-37.64(-13.46%)No. 9 UniFirst Chevy Heads to Martinsville for Final 2026 Sponsorship Appearance UniFirst Corporation (NYSE:UNF), a North American leader in providing customized business uniform programs, facility service products, and first aid...[10:00:00 AM ET]PTOP$0.010.00(0.00%)Peer To Peer Network Launches $1.99 Monthly MOBICARD Subscription, Opening Subscription Revenue Opportunity[10:00:00 AM ET]LEE$6.36+0.19(+3.00%)New Video Series, GO FIND IT! Nebraska, Celebrates the State's People, Places and Businesses[10:00:00 AM ET]SMX$1.73+0.05(+2.98%)MEDIA ALERT: TechCrunch Publishes Contributor Content Article on SMX's Digital Material Identity Technology[10:00:00 AM ET]FSV$140.27-3.89(-2.70%)FirstService Residential debuts Los Angeles episode of Skyline Sessions FirstService Residential, North America's leading residential property management company, today released the Los Angeles episode of Skyline...[10:00:00 AM ET]ALKT$15.51-0.20(-1.27%)Connexus Credit Union Renews and Expands Longstanding Partnership with Alkami to Advance Digital Banking and Grow Member Relationships Alkami Technology, Inc. (Nasdaq: ALKT) ("Alkami"), a digital sales and service platform provider for financial institutions in the U.S., today...[10:00:00 AM ET]BLKB$53.26-1.81(-3.29%)Blackbaud Recognized by the Responsible AI Institute for Commitment to Ethical Standards in Agentic AI, Generative AI, and Machine Learning Blackbaud (NASDAQ: BLKB), the world's leading provider of AI-powered solutions for social impact, today announced a series of milestones that...[10:00:00 AM ET]

ONCY · NASDAQ

Oncolytics Biotech Inc.

$0.46 -0.01 (-2.67%)

Company overview

Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on discovering and developing pharmaceutical products for the treatment of cancer. Its lead product, pelareorep, is an intravenously delivered immunotherapeutic agent for treating solid tumors and hematological malignancies. The company has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody, for treating hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer, as well as an agreement with PrECOG LLC. Incorporated in 1998, Oncolytics Biotech is headquartered in Calgary, Canada.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$46.2M
Employees
28
Headquarters
Calgary, AB
Website
oncolyticsbiotech.com
CEO
Jared Kelly
Listed
October 5, 2001
P/E
-1.37
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$22,313
Operating income
-$35.5M
EBITDA
-$36.1M
Net income
-$35.5M
EPS
-$0.34
Total assets
$8.2M
Total debt
$508,000
Earnings yield
-73.22%

Price chart

0.410.610.811.011.21
ONCY 1D NASDAQ O0.50H0.51L0.47C0.47-0.03 (-5.91%)Vol128.22K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $4. PR Newswire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy GlobeNewsWire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Reports Accelerating Enrollment in GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer GlobeNewswire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer GlobeNewsWire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer GlobeNewsWire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches GlobeNewsWire
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors GlobeNewsWire
ONCYOncolytics Biotech Inc. Stock news Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks Benzinga
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer GlobeNewsWire
ONCYOncolytics Biotech Inc. Press release Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study GlobeNewsWire
ONCYOncolytics Biotech Inc. Stock news Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths Seeking Alpha
ONCYOncolytics Biotech Inc. Stock news Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY) Defense World
ONCYOncolytics Biotech Inc. Press release Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer GlobeNewsWire
ONCYOncolytics Biotech Inc. Stock news Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of “Moderate Buy” from Analysts Defense World
See more
FAQ

Questions about Oncolytics Biotech Inc.

What does Oncolytics Biotech Inc. do?
Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on discovering and developing pharmaceutical products for the treatment of cancer. Its lead product, pelareorep, is an intravenously delivered immunotherapeutic agent for treating solid tumors and hematological malignancies. The company has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody, for treating hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer, as well as an agreement with PrECOG LLC. Incorporated in 1998, Oncolytics Biotech is headquartered in Calgary, Canada.
What is ONCY's market cap?
Oncolytics Biotech Inc. (ONCY) is a listed stock with a live quote. The latest market cap on this page is $46.2M.
Where is Oncolytics Biotech Inc. headquartered?
Oncolytics Biotech Inc. is headquartered in Calgary, AB.
How do I get ONCY news from the API?
Call GET /v1/news?tickers=ONCY. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ONCY news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ONCY, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ONCY price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs